Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

Ferreri, Andrés J. M., Ponzoni, Maurilio, Guidoboni, Massimo, De Conciliis, Carlo, Resti, Antonio Giordano, Mazzi, Benedetta, Lettini, Antonia Anna, Demeter, Judit, Dell'Oro, Stefania, Doglioni, Claudio, Villa, Eugenio, Boiocchi, Mauro and Dolcetti, Riccardo (2005) Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. Journal of Clinical Oncology, 23 22: 5067-5073. doi:10.1200/JCO.2005.07.083

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ374304_OA.pdf application/pdf 203.56KB 0

Author Ferreri, Andrés J. M.
Ponzoni, Maurilio
Guidoboni, Massimo
De Conciliis, Carlo
Resti, Antonio Giordano
Mazzi, Benedetta
Lettini, Antonia Anna
Demeter, Judit
Dell'Oro, Stefania
Doglioni, Claudio
Villa, Eugenio
Boiocchi, Mauro
Dolcetti, Riccardo
Title Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy
Formatted title
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy
Journal name Journal of Clinical Oncology   Check publisher's open access policy
ISSN 0732-183X
Publication date 2005-08-01
Year available 2005
Sub-type Article (original research)
DOI 10.1200/JCO.2005.07.083
Open Access Status File (Publisher version)
Volume 23
Issue 22
Start page 5067
End page 5073
Total pages 7
Place of publication Alexandria, VA, United States
Publisher American Society of Clinical Oncology
Language eng
Formatted abstract
Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas.

Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up.

Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (< 50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively.

Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.
Keyword Oncology
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: UQ Diamantina Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 127 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 154 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 28 Nov 2015, 05:37:38 EST by System User on behalf of Learning and Research Services (UQ Library)